All Stories

  1. A novel visualization approach for network meta-analysis: The plate plot and the nmaplateplot R package
  2. Unpublished trials affected evidence synthesis substantially when estimating medication harms in children
  3. Evidence contamination: what it is and why it matters
  4. Severity-Dependent Speech Characteristics and Clear Speech Response in Parkinson’s Disease: Perceptual, Acoustic, and Lingual Kinematic Findings
  5. Evaluating the proper use of weighted mean difference in evidence synthesis: a meta-epidemiology study
  6. On the importance of covariate-by-time interactions in longitudinal linear models
  7. Regression to the mean: a primer for evidence-based medicine practitioners
  8. BIAS, BENEFIT, OR BOTH? SURVEYING PERCEPTIONS OF AI IN HEALTHCARE
  9. Benchmarking DNA foundation models for genomic and genetic tasks
  10. An alternative method for assessing the fragility of survival analysis results: a proof-of-concept study based on the log-rank test
  11. Leveraging AI for Meta‐Analysis: Evaluating LLMs in Detecting Publication Bias for Next‐Generation Evidence Synthesis
  12. Retiring the Term “Weighted Mean Difference” in Contemporary Evidence Synthesis
  13. Lifecycles of Cochrane Systematic Reviews (2003–2024): A Bibliographic Study
  14. Prospective registration was associated with a reduced risk of bias for randomized controlled trials: a meta-research study
  15. Post‐cesarean skin closure with metal staples versus subcuticular suture in obese patients: A systematic review and meta‐analysis of randomized controlled trials
  16. Tipping point analysis in network meta-analysis
  17. Prediction Performance of Earlier Studies for Later Studies in Cochrane Reviews
  18. Lack of reproducibility of trial sequential analyses: a meta-epidemiological study
  19. Confidence intervals of the relative risk and odds ratio can predict when the optimal information size in a meta-analysis is not met
  20. Trial sequential analysis involving same-year studies requires careful temporal ordering
  21. The Role of Double‐Zero‐Event Studies in Evidence Synthesis: Evaluating Robustness Using the Fragility Index
  22. Assessment of inverse publication bias in safety outcomes: an empirical analysis
  23. Robustness Assessment of Oncology Dose-Finding Trials Using the Modified Fragility Index
  24. Towards the automatic risk of bias assessment on randomized controlled trials: A comparison of RobotReviewer and humans
  25. Meta-analysis of continuous outcomes: a user’s guide for analysis and interpretation
  26. A brief note on the common (fixed)-effect meta-analysis model: comment on Veroniki and McKenzie
  27. Comparisons of various estimates of the I2 statistic for quantifying between-study heterogeneity in meta-analysis
  28. Comparisons of the mean differences and standardized mean differences for continuous outcome measures on the same scale
  29. Structural Equation Modeling Using R/SAS: A Step-by-Step Approach with Real Data Analysis
  30. Sensitivity analysis with iterative outlier detection for systematic reviews and meta‐analyses
  31. Choice of link functions for generalized linear mixed models in meta-analyses of proportions
  32. The impact of studies with no events in both arms on meta-analysis of rare events: A simulation study using generalized linear mixed model
  33. Bayesian hierarchical models incorporating study‐level covariates for multivariate meta‐analysis of diagnostic tests without a gold standard with application to COVID‐19
  34. The Active Ingredient in Reading Comprehension Strategy Intervention for Struggling Readers: A Bayesian Network Meta-analysis
  35. Methods for deriving risk difference (absolute risk reduction) from a meta-analysis
  36. The normality assumption on between-study random effects was questionable in a considerable number of Cochrane meta-analyses
  37. Assessing the robustness of results from clinical trials and meta-analyses with the fragility index
  38. THE EFFECT DIRECTION SHOULD BE TAKEN INTO ACCOUNT WHEN ASSESSING SMALL-STUDY EFFECTS
  39. Meta-analysis methods for risk difference: A comparison of different models
  40. Data extraction error in pharmaceutical versus non-pharmaceutical interventions for evidence synthesis: Study protocol for a crossover trial
  41. Limits in the search date for rapid reviews of diagnostic test accuracy studies
  42. A Retrospective Analysis of Biological Complications of Dental Implants
  43. A Bayesian model for combining standardized mean differences and odds ratios in the same meta-analysis
  44. Synthesizing evidence from the earliest studies to support decision‐making: To what extent could the evidence be reliable?
  45. Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package
  46. Accounting for publication bias using a bivariate trim and fill meta‐analysis procedure
  47. Meta-analysis methods for risk difference: a comparison of different models
  48. Empirical comparisons of meta-analysis methods for diagnostic studies: a meta-epidemiological study
  49. Comment on a review of methods to assess publication and other reporting biases in meta‐analysis
  50. Empirical comparisons of heterogeneity magnitudes of the risk difference, relative risk, and odds ratio
  51. The Odds Ratio is “portable” across baseline risk but not the Relative Risk: Time to do away with the log link in binomial regression
  52. Bridging randomized controlled trials and single-arm trials using commensurate priors in arm-based network meta-analysis
  53. A penalization approach to random‐effects meta‐analysis
  54. Methodological quality for systematic reviews of adverse events with surgical interventions: a cross-sectional survey
  55. Predictive P-score for treatment ranking in Bayesian network meta-analysis
  56. Estimating Partial Standardized Mean Differences from Regression Models
  57. Rapid evidence synthesis approach for limits on the search date: How rapid could it be?
  58. Empirical Comparisons of 12 Meta-analysis Methods for Synthesizing Proportions of Binary Outcomes
  59. The impact of studies with no events in both arms on meta-analysis of rare events: a simulation study using generalized linear mixed model
  60. Synthesis of evidence from zero‐events studies: A comparison of one‐stage framework methods
  61. Good Statistical Practices for Contemporary Meta-Analysis: Examples Based on a Systematic Review on COVID-19 in Pregnancy
  62. Bayesian meta‐analysis using SAS PROC BGLIMM
  63. A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies
  64. Utilization of the evidence from studies with no events in meta-analyses of adverse events: an empirical investigation
  65. Methodological assessment of systematic reviews and meta‐analyses on COVID ‐19: A meta‐epidemiological study
  66. Double-zero-event studies matter: A re-evaluation of physical distancing, face masks, and eye protection for preventing person-to-person transmission of COVID-19 and its policy impact
  67. Bayesian Methods for Meta-Analyses of Binary Outcomes: Implementations, Examples, and Impact of Priors
  68. The influence of insertion torque values on the failure and complication rates of dental implants: A systematic review and meta‐analysis
  69. Many meta-analyses of rare events in the Cochrane Database of Systematic Reviews were underpowered
  70. Empirical assessment of prediction intervals in Cochrane meta‐analyses
  71. Prior Choices of Between-Study Heterogeneity in Contemporary Bayesian Network Meta-analyses: an Empirical Study
  72. Systematic identification of risk factors and drug repurposing options for Alzheimer's disease
  73. BayesSenMC: an R package for Bayesian Sensitivity Analysis of Misclassification
  74. Evidence inconsistency degrees of freedom in Bayesian network meta-analysis
  75. Protocols for meta-analysis of intervention safety seldom specified methods to deal with rare events
  76. PALM: Patient-centered Treatment Ranking via Large-scale Multivariate Network Meta-analysis
  77. Evaluation of various estimators for standardized mean difference in meta‐analysis
  78. Questionable utility of the relative risk in clinical research: a call for change to practice
  79. A Bayesian Approach for Determining the Relationship Between Various Elongate Mineral Particles (EMPs) Definitions
  80. Fragility index of network meta-analysis with application to smoking cessation data
  81. Peto odds ratios demonstrate no advantage over classic odds ratios in meta-analysis of binary rare outcomes
  82. Meta-analysis of Proportions Using Generalized Linear Mixed Models
  83. Double-zero-event studies matter: a re-evaluation of physical distancing, face masks, and eye protection for preventing person-to-person transmission of COVID-19 and its policy impact
  84. A variance shrinkage method improves arm-based Bayesian network meta-analysis
  85. Accounting for small-study effects using a bivariate trim and fill meta-analysis procedure
  86. Arcsine‐based transformations for meta‐analysis of proportions: Pros, cons, and alternatives
  87. Systematic identification of modifiable risk factors and drug repurposing options for Alzheimer’s disease: Mendelian randomization analyses
  88. Exclusion of studies with no events in both arms in meta-analysis impacted the conclusions
  89. Effects of treatment classifications in network meta-analysis
  90. A Bayesian approach to assessing small‐study effects in meta‐analysis of a binary outcome with controlled false positive rate
  91. Laplace approximation, penalized quasi-likelihood, and adaptive Gauss–Hermite quadrature for generalized linear mixed models: towards meta-analysis of binary outcome with sparse data
  92. Factors that impact fragility index and their visualizations
  93. The impact of covariance priors on arm‐based Bayesian network meta‐analyses with binary outcomes
  94. Hybrid test for publication bias in meta-analysis
  95. P value–driven methods were underpowered to detect publication bias: analysis of Cochrane review meta-analyses
  96. On evidence cycles in network meta-analysis
  97. Use of Prediction Intervals in Network Meta-analysis
  98. The magnitude of small-study effects in the Cochrane Database of Systematic Reviews: an empirical study of nearly 30 000 meta-analyses
  99. Comparison of four heterogeneity measures for meta‐analysis
  100. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses
  101. Real-world Performance of Meta-analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews
  102. Graphical augmentations to sample-size-based funnel plot in meta-analysis
  103. Borrowing of strength from indirect evidence in 40 network meta-analyses
  104. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation
  105. Performance of Between-study Heterogeneity Measures in the Cochrane Library
  106. Re: Incidence and Risk Factors for Prediabetes and Diabetes Mellitus Among HIV-infected Adults on Antiretroviral Therapy: A Systematic Review and Meta-analysis
  107. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model
  108. Bias caused by sampling error in meta-analysis with small sample sizes
  109. Quantifying and presenting overall evidence in network meta-analysis
  110. Empirical Comparison of Publication Bias Tests in Meta-Analysis
  111. The effect of publication bias magnitude and direction on the certainty in evidence
  112. Bayesian multivariate meta-analysis of multiple factors
  113. Quantifying publication bias in meta-analysis
  114. Rejoinder to “quantifying publication bias in meta-analysis”
  115. Cross channel effects of search engine advertising on brick & mortar retail sales: Meta analysis of large scale field experiments on Google.com
  116. Performing Arm-Based Network Meta-Analysis in R with the pcnetmeta Package
  117. An adaptive two-sample test for high-dimensional means
  118. Sensitivity to Excluding Treatments in Network Meta-analysis
  119. Alternative measures of between-study heterogeneity in meta-analysis: Reducing the impact of outlying studies